Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules
Conditions: Primary Immune Deficiency; Secondary Immune DeficiencyIntervention: Biological: Subcutaneous Immune Globulin (Human) (Hizentra)Sponsor: CSL BehringRecruiting - verified February 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2016 Category: Research Source Type: clinical trials